Establishment of donor Chimerism Using Allogeneic Bone Marrow with AMP Cell Co-infusion
Technical Report,15 Aug 2016,14 Aug 2017
Columbia University Medical Center New York United States
Pagination or Media Count:
Composite tissue allografts CTA have been more and more frequently used to treat combat-associated injuries, however, rejection remains to be the major barrier that could not be solved by potent non-specific immunosuppression. Induction of tolerance to the CTA is the ideal solution. Combined mixed allogeneic chimerism induction and kidney transplantation has been shown to induce robust tolerance to the kidney allograft despite transient mixed chimerism in non-human primates and humans. Evidence suggests that durable mixed chimerism may be required for tolerance induction of all types of allografts. In this study, we investigate whether co-infusion of amnion-derived multipotent progenitor AMP cells, which have unique immunomodulatory properties, can promote durable mixed allogeneic chimerism induction in a non-human primate model. Results suggest that intravenous infusion of high dose of 3rd party AMP cells did not lead to prolonged mixed chimerism, which was associated with the inability of AMP cells to traffic to or persist in the target organs. We will determine whether intrabone injection of AMP cells will allow these cells to exert their immunosuppressive activities to promote durable mixed chimerism induction.
- Medicine and Medical Research
- Anatomy and Physiology